{
    "organizations": [],
    "uuid": "94d16376d52915323d96abc9c5d43d618d4da2bc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-benitec-biopharma-launches-entitle/brief-benitec-biopharma-launches-entitlement-offer-and-placement-idUSFWN1S605Q",
    "ord_in_thread": 0,
    "title": "BRIEF-Benitec Biopharma Launches Entitlement Offer And Placement",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - Benitec Biopharma Ltd:\n* LAUNCHED ENTITLEMENT OFFER TO ELIGIBLE SHAREHOLDERS AND INSTITUTIONAL PLACEMENT TO HIGHBRIDGE CAPITAL MANAGEMENT LLC\n* WILL ISSUE 772,201 AMERICAN DEPOSITARY SHARES (ADS) TO HIGHBRIDGE; ISSUE PRICE UNDER PLACEMENT US$2.59 PER ADS\n* 1 FOR 2 PRO RATA RENOUNCEABLE ENTITLEMENT OFFER TO ELIGIBLE SHAREHOLDERS AT AUD 17 CENTS Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-30T09:19:00.000+03:00",
    "crawled": "2018-04-30T13:18:36.000+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "benitec",
        "biopharma",
        "ltd",
        "launched",
        "entitlement",
        "offer",
        "eligible",
        "shareholder",
        "institutional",
        "placement",
        "highbridge",
        "capital",
        "management",
        "llc",
        "issue",
        "american",
        "depositary",
        "share",
        "ad",
        "highbridge",
        "issue",
        "price",
        "placement",
        "u",
        "per",
        "ad",
        "pro",
        "rata",
        "renounceable",
        "entitlement",
        "offer",
        "eligible",
        "shareholder",
        "aud",
        "cent",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}